Annual report for the Association for Accessible Medicines recapping 2010. View press release to learn more about the successful rebrand.
2010 was a year of profound change. The enactment of new healthcare laws radically altered state and federal regulations governing medical care. New legislation authorized the FDA to create an approval process for generic biologic products. The escalating use of generic prescription drugs pushed annual U.S. sales of generics to a record high $50 billion. And at GPhA, we implemented a comprehensive restructuring plan that positioned the Association as a stronger, and more focused advocate for its membership.
As we look back at 2010, we realize that the events of last year laid the foundation on which we now have the opportunity to build a healthier future for our industry and the consumers we serve. We move into 2011 with a clear vision of our critical mission: To execute a winning advocacy strategy that optimizes the regulatory and political environments to fully expand the advantages offered by generic and biogeneric medicines.